Home > News > Osmetech grants research license to Minerva for monolayer technology
June 18th, 2007
Osmetech grants research license to Minerva for monolayer technology
Abstract:
Osmetech PLC said it has granted a non-exclusive research license to US-based Minerva Biotechnologies Corp for use of its self-assembling monolayer technology in tandem with Minerva's proprietary nanoparticle technology.
Financial terms of the deal were not disclosed.
The molecular diagnostics company said Minerva plans to use the technology for signal enhancement, drug design, drug screening, and functional proteomics.
Source:
hemscott.com
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||